Document:

<PAGE>

EXHIBIT 10.41

--------------------------------------------------------------------------------

                              AETHLON MEDICAL, INC.

                             SUBSCRIPTION AGREEMENT

--------------------------------------------------------------------------------

IN MAKING AN INVESTMENT DECISION INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF
THE PERSON OR ENTITY ISSUING THE UNITS AND THE TERMS OF THE OFFERING, INCLUDING
THE MERITS AND RISKS INVOLVED. THE UNITS BEING OFFERED HEREBY HAVE NOT BEEN
RECOMMENDED BY ANY FEDERAL OR STATE SECURITIES COMMISSION OR REGULATORY
AUTHORITY. FURTHERMORE THE FOREGOING AUTHORITIES HAVE NOT CONFIRMED THE ACCURACY
OR DETERMINED THE ADEQUACY OF THIS DOCUMENT.

THESE UNITS AND THE UNDERLYING SECURITIES ARE SUBJECT TO RESTRICTIONS ON
TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS
PERMITTED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE APPLICABLE STATE
SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. INVESTORS
SHOULD BE AWARE THAT THEY WILL BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS
INVESTMENT FOR AN INDEFINITE PERIOD OF TIME.

<PAGE>

                             SUBSCRIPTION AGREEMENT

     The undersigned (hereinafter "SUBSCRIBER") hereby confirms its subscription
for the purchase of Units comprised of shares of Common Stock, par value $.001
per share ("Common Stock"), of AETHLON MEDICAL, INC., a Nevada corporation (the
"COMPANY"), and warrants exercisable for Common Stock ("Warrants"), on the terms
described below.

     The Units, the Common Stock, the Warrants and the shares issuable upon
exercise of the Warrants ("Warrant Shares") are sometimes referred to
collectively herein as the "SECURITIES."

     In connection with this subscription, Subscriber and the Company agree as
follows:

A.   Subscription of the Subscriber.

     1. Purchase of Units. The undersigned (the "Subscriber") hereby irrevocably
agrees, represents and warrants with, to and for the benefit of the Company,
that such Subscriber is executing this Agreement in connection with the
subscription by the Subscriber for _______ units of the Company ("Units"), with
each Unit consisting of (i) two shares of Common Stock of the Company and (ii)
one Warrant to purchase one share of Common Stock of the Company for an exercise
price of $0.50 per share, at a price per Unit of $1.00, resulting in the
aggregate purchase price set forth on the Subscriber's signature page hereto
(the "Offering Price"). The Common Stock and the Warrants (and the Warrant
Shares) are sometimes referred to hereinafter collectively as the "Underlying
Stock". The Subscriber understands that the Company is relying upon the accuracy
and completeness of the information contained herein in complying with its
obligations under federal and state securities and other applicable laws.
Subject to the terms and conditions of this Agreement, upon execution and
delivery hereof by the Subscriber, the Subscriber hereby agrees to purchase the
Units of the Company pursuant to the transaction hereof, and against concurrent
delivery of the purchase price for such Units. The date upon which the final
subscription is accepted by the Company and the full Offering Price has been
tendered to the Company, shall be known as the "Closing Date."

     2. Offering. This offering of the Units (the "Offering") is being made to a
limited group of investors, all of whom shall represent to the Company pursuant
to this Agreement that they are "accredited investors," as that term is defined
in Regulation D promulgated under the Securities Act of 1933, as amended (the
"Securities Act") or who have otherwise been qualified as investors by the
Company. All of the Units offered hereby are being sold by the Company. The
Company is offering Units for the consideration set forth herein. The Company
may sell less than all of the Units, and shall be entitled to accept
subscriptions and receive the Offering Price for each subscription prior to the
entire Offering being subscribed for. The Offering is being made on a "best
efforts" basis. The minimum subscription amount is $25,000.

B.   Representations and Warranties of the Subscriber. The Subscriber hereby
represents and warrants to the Company as of the date hereof:

     1. Place of Business. The principal place of business address set forth
below is such Subscriber's true and correct principal place of business and is
the only jurisdiction in which an offer to sell the Units was made to such
Subscriber and such Subscriber has no present intention of moving its principal
place of business to or of becoming a resident of any other state or
jurisdiction.

                                      -1-
<PAGE>

     2. Sale or Transfer of the Units and Underlying Stock. The Subscriber
understands that neither the Units nor any of the Underlying Stock has been
registered under the Securities Act, or under the laws of any other
jurisdiction. The Subscriber understands and agrees that transfer or sale of the
Units and the Underlying Stock may be restricted or prohibited unless they are
subsequently registered under the Securities Act and, where required, under the
laws of other jurisdictions or an exemption from registration is available. The
Subscriber will not offer, sell, transfer or assign its Units or Underlying
Stock or any interest therein in contravention of this Agreement, the Securities
Act or any state or federal law. The Subscriber understands and acknowledges
that, because of the substantial restrictions on the transferability of the
Units and Underlying Stock, it may not be possible for the Subscriber to
liquidate the Subscriber's investment in the Company readily, even in the case
of an emergency.

     3. Representation of Accredited Investor Status, Investment Experience and
Ability to Bear Risk. Subscriber acknowledges that the Offering has not been
registered with the Securities and Exchange Commission because the Company is
relying on an exemption from registration under Section 4(2) of the Securities
Act and Regulation D promulgated thereunder. SUBSCRIBER BELIEVES THAT AT THE
TIME OF THE SALE OF THE UNITS TO SUBSCRIBER, SUBSCRIBER (OR, IF SUBSCRIBER IS A
CORPORATION, LIMITED LIABILITY COMPANY OR TRUST, EACH OF ITS EQUITY OWNERS)
QUALIFIES AS AN "ACCREDITED INVESTOR" (AS DEFINED UNDER RULE 501 OF REGULATION D
PROMULGATED UNDER THE SECURITIES ACT) USING THE FOLLOWING QUALIFICATION FACTORS
(CHECK ALL APPROPRIATE ITEMS):

(__) $1,000,000 NET WORTH TEST:

     I, Subscriber, am a natural person and my individual net worth, or joint
     net worth with my spouse (if any), INCLUSIVE of home, furnishings and
     automobiles, at the time of this purchase is in excess of $1,000,000.

(__) $200,000 INDIVIDUAL/$300,000 JOINT ANNUAL INCOME TEST:

     I, Subscriber, am a natural person and my individual annual gross income
     (exclusive of my spouse's income) has been in excess of $200,000 in each of
     the two most recent tax years, and I reasonably expect individual annual
     gross income (exclusive of my spouse's income) to be in excess of $200,000
     for the current tax year; or I am a natural person and my joint annual
     gross income (including my spouse's annual gross income) has been in excess
     of $300,000 in each of the two most recent tax years, and I reasonably
     expect our joint annual gross incomes to be in excess of $300,000 for the
     current tax year.

     ("INCOME" under this test is defined as adjusted gross income for federal
     income tax purposes PLUS (i) deductions for long-term capital gains under
     the Internal Revenue Code; (ii) deductions for depletion under section 611
     et seq. of the Code; (iii) any exclusion for interest received on
     tax-exempt securities; and (iv) any losses of a Company allocated to the
     individual limited partners of the Company as reported on Form 1040).

                                      -2-
<PAGE>

(__) BANK OR INVESTMENT COMPANY TEST:

     Subscriber is a bank as defined in section 3(a)(2) of the Securities Act,
     or any savings and loan association or other institution as defined in
     section 3(a)(5)(A) of the Securities Act, whether acting in its individual
     or fiduciary capacity; or is a broker or dealer registered pursuant to
     section 15 of the Securities Exchange Act of 1934; or is an insurance
     company as defined in section 2(13) of the Securities Act; or is any
     investment company registered under the Investment Corporation Act of 1940,
     or a business development company as defined in section 2(a)(48) of that
     Act; or is a Small Business Investment Corporation licensed by the U.S.
     Small Business Administration under section 301(c) or (d) of the Small
     Business Investment Act of 1958; is a plan established and maintained by a
     state, its political subdivision, or any agency or instrumentality of a
     state or its political subdivisions, for the benefit of its employees, if
     such plan has total assets in excess of $5,000,000; or is an employee
     benefit plan within the meaning of the employee Retirement Income Security
     Act of 1974, if the investment decision is made by a plan fiduciary, as
     defined in section 3(21) of such Act, which is either a bank, savings and
     loan association, insurance company, or registered investment adviser, or
     if the employee benefit plan has total assets in excess of $5,000,000, or,
     if a self-directed plan, with investment decisions made solely by persons
     that are accredited investors.

(__) PRIVATE BUSINESS DEVELOPMENT CORPORATION TEST:

     Subscriber is a private business development company as defined in section
     202(a)(22) of the Investment Advisors Act of 1940.

(__) IRC SECTION 501(C)(3) ORGANIZATION TEST:

     Subscriber is an organization described in Section 501(c)(3) of the
     Internal Revenue Code, corporation, Massachusetts or similar business
     trust, or Company, not formed for the specific purpose of acquiring the
     securities being offered, with total assets in excess of $5,000,000.

(__) DIRECT RELATIONSHIP TO ISSUER TEST:

     Subscriber is a director, executive officer, partner or manager of the
     Company of the securities being offered or sold, or any director, executive
     officer or manager of a partner or partner of that issuer.

(__) $5,000,000 NONINVESTMENT TRUST TEST:

     Subscriber is a trust with total assets in excess of $5,000,000 not formed
     for the specific purpose of acquiring the securities being offered, whose
     purchase is directed by a "sophisticated person" as described in section
     230.506(b)(2)(ii).

                                      -3-
<PAGE>

(__) EQUITY ENTITY COMPRISED OF ACCREDITED INVESTORS TEST:

     Subscriber is any equity entity in which all of the equity owners are
     accredited investors as defined above. Subscriber has had one of the
     persons responsible for overseeing and/or managing one or more of
     Subscriber's financial accounts complete the attestation in Section D
     hereof in order to verify the information in this Section B:

     Yes _________   No _________

In addition, Subscriber is knowledgeable and experienced with respect to the
financial and business activities contemplated by the Company and is capable of
evaluating the risks and merits of investing in the Units and, in making a
decision to proceed with this investment, has not relied upon any
representations, warranties or agreements, other than those set forth in this
Agreement and can bear the economic risk of an investment in the Company for an
indefinite period of time, and can afford to suffer the complete loss thereof.

     4. Own Advice. In connection with the Subscriber's investment in the
Company, the Subscriber has carefully considered and has, to the extent the
Subscriber believes such discussion necessary, discussed with the Subscriber's
professional legal, tax and financial advisers (the "Investment Advisors") the
suitability of an investment in the Units for the Subscriber's particular tax
and financial situation and the Subscriber has determined that the Units are a
suitable investment for the Subscriber.

     5. Company History; Risks. The Subscriber represents and warrants that the
Subscriber is aware (i) that the Company has limited operating history; (ii)
that the Units involve a substantial degree of risk of loss of the Subscriber's
entire investment and that there is no assurance of any income from the
Subscriber's investment; and (iii) that any federal and/or state income tax
benefits which may be available to the Subscriber, if any, may be lost through
the adoption of new laws or regulations, to changes to existing laws and
regulations and to changes in the interpretation of existing laws and
regulations. The Subscriber further represents that the Subscriber is relying
solely on the Subscriber's own conclusions or the advice of the Subscriber's
Investment Advisors with respect to tax aspects of any investment in the Units.

     6. Inquiries. The Subscriber and its Investment Advisors have been given
access to, and prior to the execution of this Agreement, have been provided with
an opportunity to ask questions of, and receive answers from, the Company
officers concerning the Company and the terms and conditions of the Offering and
the Units, and to obtain any other information which the Subscriber and the
Subscriber's Investment Advisors required with respect to the Company and an
investment in the Company in order to evaluate such investment and verify the
accuracy of all information furnished to the Subscriber and its Investment
Advisors regarding the Company. All such questions, if asked, were answered
satisfactorily and all information or documents provided were found to be
satisfactory. Neither the Subscriber nor its Investment Advisors have been
furnished any offering literature on which they have relied on other this
Agreement and the Subscriber and its Investment Advisors have relied only on
this Agreement. At no time was the Subscriber presented with or solicited by any
leaflet, public promotion meeting, newspaper or magazine article, radio or
television advertisement or any other form of general advertising or general
solicitation.

                                      -4-
<PAGE>

     7. Authority. The Subscriber is authorized and has full right and power to
subscribe for the Units and to perform the Subscriber's obligations pursuant to
the provisions of this Agreement; the person signing this Agreement and any
other instrument executed and delivered herewith on behalf of such Subscriber
has been duly authorized by such entity and has full power and authority to do
so. If the Subscriber is a corporation, partnership, unincorporated association
or other entity, the person signing this agreement has the legal capacity to
authorize, deliver and be bound by this Subscription Agreement and to take all
actions required pursuant hereto and further certifies that all necessary
approvals of directors, shareholders or otherwise have been given and obtained;
and if the Subscriber is an individual, it is of the full age of majority in the
jurisdiction in which the Subscriber is resident and is legally competent to
execute, deliver and be bound by this Subscription Agreement and take all action
pursuant hereto.

     8. No Default. The execution and delivery of this Agreement and the
consummation of the transactions contemplated hereby and thereby will not
conflict with, or result in any violation of or default pursuant to, any
provision of any governing instrument applicable to the Subscriber, or any
agreement or other instrument to which the Subscriber is a party or by which the
Subscriber or any of the Subscriber's properties are bound or any permit,
franchise, judgment, decree, statute, rule or regulation applicable to the
Subscriber or any of the Subscriber's business or properties.

     9. ERISA. If the Subscriber is an employee benefit plan subject to ERISA,
then such Subscriber acknowledges that such Subscriber has been informed of and
understands the operations and business of the Company, and represents that such
Subscriber's investment in the Company (i) is permissible under the documents
and instruments governing such plan; (ii) satisfies the diversification
requirements of ERISA; (iii) is prudent considering all the facts and
circumstances, including the fact that there is no trading market for the Units
or the Underlying Stock; and (iv) is not a "prohibited transaction" within the
meaning of Section 406 of ERISA.

     10. Purchase Entirely For Own Account. This Agreement is made with the
Subscriber in reliance upon the Subscriber's representations to the Company,
which by the Subscriber's execution of this Agreement, the Subscriber hereby
confirms, that the Units issuable to the Subscriber will be acquired for
investment for the Subscriber's own account, not as a nominee or agent, and not
with a view to the resale or distribution of any part thereof, and that the
Subscriber has no present intention of selling, granting any participation in,
or otherwise distributing the same. The Subscriber represents and warrants that
the Subscriber has no contract, understanding, agreement or arrangement with any
person to sell or transfer or pledge to such person or anyone else any of the
Units for which the Subscriber hereby subscribes (in whole or in part) or any
interest therein; and the Subscriber represents and warrants that the Subscriber
has no present plans to enter into any such contract, undertaking, agreement or
arrangement.

     The Subscriber represents and warrants that the funds representing the
Aggregate Subscription Price which will be advanced by the Subscriber hereunder
will not represent proceeds of crime and the Subscriber acknowledges that the
Company or the Placement Agents may in the future be required by law to disclose
the Subscriber's name and other information relating to this Subscription
Agreement and the Subscriber's subscription hereunder, on a confidential basis,
and to the best of the Subscriber's knowledge (i) none of the subscription funds
to be provided by the Subscriber (a) have been or will be derived from or
related to any activity that is deemed criminal under the laws of the United
States of America, or any other jurisdiction, or (b) are being tendered on
behalf of a person or entity who has not been identified to the Subscriber, and
(ii) it shall promptly notify the Company and the Placement Agents if the
Subscriber discovers that any of such representations ceases to be true, and to
provide the Company and the Placement Agents with appropriate information in
connection therewith.

                                      -5-
<PAGE>

The Subscriber represents and warrants that the current structure of this
transaction and all transactions and activities contemplated hereunder is not a
plan or scheme to evade the registration provisions of the Securities Act.

The Subscriber acknowledges that:

     (i)  no securities commission or similar regulatory authority has reviewed
          or passed on the merits of the Units or the Underlying Stock; and

     (ii) there is no government or other insurance covering the Units or
          Underlying Stock; and

     (iii) there are risks associated with the purchase of the Units; and

     (iv) there are restrictions on the Subscriber's ability to resell the Units
          and the Underlying Stock and it is the responsibility of the
          Subscriber to find out what those restrictions are and to comply with
          them before selling the Units and the Underlying Stock; and

     (v)  the Company has advised the Subscriber that the Company is relying on
          an exemption from the requirements to provide the Subscriber with a
          prospectus and to sell securities through a person or company
          registered to sell securities under applicable securities laws and, as
          a consequence of acquiring the Units pursuant to this exemption,
          certain protections, rights and remedies provided by applicable
          securities laws, including statutory rights of rescission or damages,
          will not be available to the Subscriber.

The Subscriber represents and warrants that it has not received nor does it
expect to receive any financial assistance from the Company, directly or
indirectly, in respect of the Subscriber's purchase of the Units.

The Subscriber represents and warrants that neither the Company nor the
Placement Agents, nor any of their respective directors, officers, employees or
representatives, have made any representations (oral or written) to the
Subscriber regarding the future value of the Units or the Underlying Stock.

The Subscriber acknowledges that (i) the Company may complete secured or
unsecured debt financings or equity financings in the future in order to develop
the Company's business and to fund its ongoing development, (ii) there is no
assurance that such financings will be available and, if available, on
reasonable terms, (iii) any such future financings may have a dilutive effect on
current security holders, including the Subscriber, and (iv) if such future
financings are not available, the Company may be unable to fund its ongoing
development and the lack of capital resources may result in the failure of its
business.

                                      -6-
<PAGE>

The Subscriber acknowledges that the Placement Agents, their respective
affiliates and their respective directors, officers, employees and companies
with which they are associated may, from time to time, have a long or short
position or deal as principal in the securities of the Company.

C.   Representations and Warranties of the Company.

     1. Organization, Good Standing and Qualification. The Company is a
corporation duly organized, validly existing, in good standing under the laws of
the State of Nevada and has all requisite corporate power and corporate
authority to carry on its business as now conducted and as proposed to be
conducted. The Company is duly qualified to transact business and is in good
standing in the State of Nevada. The Company is duly qualified to transact
business and is in good standing in each jurisdiction in which such
qualification is required, except where the failure to be so qualified would not
have a material adverse effect on the Company.

     2. Finders Fees. A finder's fee of up to 7% of the amounts subscribed for
may be paid to anyone acting as a finder in this Offering. Such fee, if any,
shall be payable one-half in cash and one-half in Units.

     3. Capitalization. As of consummation of the transactions contemplated
hereby and immediately thereafter, the authorized capital stock of the Company
shall consist of 100,000,000 shares of common stock, par value $0.001 per share
(the "Common Stock"), of which (i)__________ shares shall be issued and
outstanding, (ii) shares are reserved for issuance upon exercise of outstanding
warrants, options and other convertible securities, and (iii) _____ shares shall
be reserved for issuance upon the exercise of the Warrants . All such issued and
outstanding shares have been duly authorized and validly issued and have been
offered, issued, sold, and delivered by the Company in compliance with
applicable federal and state securities laws.

     4. Authorization. The Company has all requisite corporate power to execute,
deliver and perform its obligations under this Agreement and all other
agreements contemplated hereby and thereby and to issue the Units and the
Underlying Stock in accordance with the terms hereof. All corporate action on
the part of the Company, its officers, directors and shareholders necessary for
the authorization, execution and delivery of this Agreement and all other
agreements and obligations contemplated hereby and thereby, the performance of
all obligations of the Company hereunder and thereunder, and the authorization,
issuance (or reservation for issuance), sale and delivery of the Common Stock to
be issued hereunder has been taken. This Agreement constitutes valid and legally
binding obligations of the Company, enforceable in accordance with their
respective terms, except (i) as limited by applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting
enforcement of creditors' rights generally, (ii) as limited by general
principles of equity, including concepts of materiality, reasonableness, good
faith and fair dealing and by the possible unavailability of specific
performance, injunctive relief or other equitable remedies.

                                      -7-
<PAGE>

     5. No Violation. The Company's execution, delivery and performance of this
Agreement and all other agreements contemplated hereby and thereby and the
consummation of the transactions contemplated hereby and thereby will not with
or without the giving of notice or the lapse of time or both (A) violate any
provision of law, statute, rule or regulation to which the Company is subject,
(B) violate any order, judgment or decree applicable to it, or (C) conflict with
or result in a breach or default under any term or condition of its applicable
governing instruments or any agreement or other instrument to which it is a
party or by which it is bound.

     6. Valid Issuance of Common Stock. The Common Stock being issued hereunder,
when issued, sold and delivered in accordance with the terms of this Agreement
for the consideration expressed herein, will be duly and validly issued, fully
paid and nonassessable and will be free of preemptive rights and restrictions on
transfer other than restrictions on transfer under this Agreement and applicable
state and federal securities laws. Assuming the truth and accuracy of the
representations and warranties of each of the Subscribers for the Company's
capital stock under agreements similar to this Agreement, the issuance of the
Units hereunder shall be exempt from registration under the Securities Act and
any applicable state securities laws.

     7. Governmental Consents. No consent, approval, order or authorization of,
or registration, qualification, designation, declaration or filing with, any
federal, state or local governmental authority on the part of the Company is
required in connection with the valid execution of this Agreement and the
consummation of the transactions contemplated by this Agreement except for
filings pursuant to applicable state and federal securities laws which allow
filings to be made following the Closing but in no event later than 15 days
after the consummation of the transactions contemplated hereby. The Company (a)
is not a Person described or designated in the Specially Designated Nationals
and Blocked Persons List of the Office of Foreign Assets Control or in Section 1
of the Anti-Terrorism Order or (b) does not engage in any dealings or
transactions with any such Person. The Company is in compliance, in all material
respects, with the USA Patriot Act.

     8. Use of Proceeds. The proceeds from the sale of Units will be available
for the Company's general corporate purposes. Up to 7% of the proceeds may be
paid for finders fees which will be paid one-half in cash and one-half in Units
at the Offering Price.

     9. No Subsidiaries. The Company has four dormant wholly-owned subsidiaries,
Aethlon, Inc, Cell Activation, Inc., Syngen Research, Inc. and Hemex, Inc.

     10. Registration Rights

  (a) Subject to the terms and limitations hereof, the Company shall file a
registration statement on Form SB-2 or other appropriate registration document
under the Securities Act (the "Registration Statement") for resale of the Common
Stock and Warrant Shares underlying the Warrants (the "Registrable Securities")
and shall use its reasonable best efforts to maintain the Registration Statement
effective so long as any of the Warrants are outstanding (the "Effectiveness
Period"). The Company shall file such Registration Statement no later than sixty
(60) days after the completion of the Offering (the "Closing Date"); provided,
however, the Company will not be obligated to register more than 33% of its
issued and outstanding shares of Common Stock on such registration statement. If
the number of shares of Common Stock and the Warrant Shares exceeds such 33%
limitation, the Company will cut back the number of shares being registered in
order for it to adhere to such 33% limitation, and such cut back will be applied

                                      -8-
<PAGE>

to the holders of the Units on a pro rata basis. The Company shall also use its
best efforts to ensure that such Registration Statement is declared effective
within one hundred and eighty (180) calendar days from the Closing Date. If the
event the Registration Statement is not declared effective within one hundred
and eighty (180) calendar days from the Closing Date (the "Effective Date"), the
Subscriber will be entitled to receive from the Company, without additional
consideration, additional shares of Common Stock equal to two percent (2%) of
the shares of Common Stock sold in the Offering for each 30-day period (or
portion thereof) after which the Effective Date has passed and the Registration
Statement remains without effectiveness. No "penalty shares" shall accrue or be
issuable if at such time the Registrable Securities may be resold pursuant to
Rule 144 under the Act.

  (b) Notwithstanding the foregoing, the Company shall not be obligated to
effect any registration of the Registrable Securities or take any other action
pursuant to this Section 10: (i) in any particular jurisdiction in which the
Company would be required to execute a general consent to service of process in
effecting such registration, qualification or compliance unless the Company is
already subject to service in such jurisdiction and except as may be required by
the Securities Act, or (ii) during any period in which the Company suspends the
rights of a Subscriber after giving the Subscriber written notification of a
Potential Material Event (defined below) pursuant to subsection (i) below.

  (c) Except as otherwise expressly set forth, the Company shall bear all
expenses incurred by the Company in compliance with the registration obligation
of the Company, including, without limitation, all registration and filing fees,
printing expenses, fees and disbursements of counsel for the Company incurred in
connection with any registration, qualification or compliance pursuant to this
Subscription Agreement and all underwriting discounts, selling commissions and
expense allowances applicable to the sale of any securities by the Company for
its own account in any registration. All underwriting discounts, selling
commissions and expense allowances applicable to the sale by Subscriber of
Registrable Securities and all fees and disbursements of counsel for the
Subscriber shall be borne by the Subscriber.

  (d) To the extent permitted by law the Company will indemnify each Subscriber,
each of its officers, directors, agents, employees and partners, and each person
controlling such Subscriber, with respect to each registration, qualification or
compliance effected pursuant to this Agreement, and each underwriter, if any,
and each person who controls any underwriter, and their respective counsel
against all claims, losses, damages and liabilities (or actions, proceedings or
settlements in respect thereof) arising out of or based on (i) any untrue
statement (or alleged untrue statement) of a material fact contained in any
prospectus, offering circular or other document prepared by the Company
(including any related registration statement, notification or the like)
incident to any such registration, qualification or compliance, or (ii) any
omission (or alleged omission) to state therein a material fact required to be
stated therein or necessary to make the statements therein not misleading, or
any violation by the Company of the Securities Act or any rule or regulation
thereunder applicable to the Company and relating to action or inaction required
of the Company in connection with any such registration, qualification or
compliance, and subject to the provisions of subsection (g) below, will
reimburse each such Subscriber, each of its officers, directors, agents,
employees and partners, and each person controlling such Subscriber, each such
underwriter and each person who controls any such underwriter, for any legal and
any other expenses as they are reasonably incurred in connection with

                                      -9-
<PAGE>

investigating and defending any such claim, loss, damage, liability or action,
provided that the Company will not be liable in any such case to the extent that
any such claim, loss, damage, liability or expense arises out of or is based on
any untrue statement (or alleged untrue statement) or omission (or alleged
omissions) based upon written information furnished to the Company by (or on
behalf of) such Subscriber or underwriter, or if the person asserting any such
loss, claim, damage or liability (or action or proceeding in respect thereof)
did not receive a copy of an amended preliminary prospectus or the final
prospectus (or the final prospectus as amended and supplemented) at or before
the written confirmation of the sale of such Registrable Securities to such
person because of the failure of the Subscriber or underwriter to so provide
such amended preliminary or final prospectus (or the final prospectus as amended
and supplemented); provided, however, that the indemnity agreement contained in
this subsection shall not apply to amounts paid in settlement of any such loss,
claim, damage, liability or action if such settlement is effected without the
consent of the Company (which consent shall not be unreasonably withheld), nor
shall the Company be liable in any such case for any such loss, claim, damage,
liability or action to the extent that it arises out of or is based upon a
violation which occurs in reliance upon and in conformity with written
information furnished expressly for use in connection with such registration by
the Subscriber, any such partner, officer, director, employee, agent or
controlling person of such Subscriber, or any such underwriter or any person who
controls any such underwriter; provided, however, that the obligations of the
Company hereunder shall be limited to an amount equal to the portion of net
proceeds represented by the Registrable Securities pursuant to this Agreement.

  (e) To the extent permitted by law, each Subscriber whose Registrable
Securities are included in any registration, qualification or compliance
effected pursuant to this Subscription Agreement will indemnify the Company, and
its directors, officers, agents, employees and each underwriter, if any, of the
Company's securities covered by such a registration statement, each person who
controls the Company or such underwriter within the meaning of the Securities
Act and the rules and regulations thereunder, each other such Subscriber and
each of their officers, directors, partners, agents and employees, and each
person controlling such Subscriber, and their respective counsel against all
claims, losses, damages and liabilities (or actions in respect thereof) arising
out of or based on any untrue statement (or alleged untrue statement) of a
material fact contained in any such registration statement, prospectus, offering
circular or other document, or any omission (or alleged omission) to state
therein a material fact required to be stated therein or necessary to make the
statements therein not misleading, and will reimburse the Company and such
Subscribers, directors, officers, partners, persons, underwriters or control
persons for any legal or any other expenses as they are reasonably incurred in
connection with investigating or defending any such claim, loss, damage,
liability or action, in each case to the extent, but only to the extent, that
such untrue statement (or alleged untrue statement) or omission (or alleged
omission) is made in such registration statement, prospectus, offering circular
or other document in reliance upon and in conformity with written information
furnished to the Company by such Subscriber; provided, however, that the
obligations of any Subscriber hereunder shall be limited to an amount equal to
the net proceeds to such Subscriber from Registrable Securities sold under such
registration statement, prospectus, offering circular or other document as
contemplated herein; provided, further, that the indemnity agreement contained
in this subsection shall not apply to amounts paid in settlement of any such
loss, claim, damage, liability or action if such settlement is effected without
the consent of the Subscriber, which consent shall not be unreasonably withheld
or delayed.

                                      -10-
<PAGE>

  (f) Each party entitled to indemnification under this Section (the
"Indemnified Party") shall give notice to the party required to provide
indemnification (the "Indemnifying Party") promptly after such Indemnified Party
has actual knowledge of any claim as to which indemnity may be sought, and shall
permit the Indemnifying Party to assume the defense of any such claim or any
litigation resulting therefrom, provided that counsel for the Indemnifying
Party, who shall conduct the defense of such claim or any litigation resulting
therefrom, shall be approved by the Indemnified Party (whose approval shall not
unreasonably be withheld), and the Indemnified Party may participate in such
defense at such party's expense; and provided further that if any Indemnified
Party reasonably concludes that there may be one or more legal defenses
available to it that are not available to the Indemnifying Party, or that such
claim or litigation involves or could have an effect on matters beyond the scope
of this Agreement, then the Indemnified Party may retain its own counsel at the
expense of the Indemnifying Party; and provided further that the failure of any
Indemnified Party to give notice as provided herein shall not relieve the
Indemnifying Party of its obligations under this Agreement unless and only to
the extent that such failure to give notice results in material prejudice to the
Indemnifying Party. No Indemnifying Party, in the defense of any such claim or
litigation, shall, except with the consent of each Indemnified Party, consent to
entry of any judgment or enter into any settlement which does not include as an
unconditional term thereof the giving by the claimant or plaintiff to such
Indemnified Party of a release from all liability in respect to such claim or
litigation. Each Indemnified Party shall furnish such information regarding
itself or the claim in question as an Indemnifying Party may reasonably request
in writing and as shall be reasonably required in connection with defense of
such claim and litigation resulting therefrom.

  (g) If the indemnification provided for in this Section is held by a court of
competent jurisdiction to be unavailable to an Indemnified Party with respect to
any loss, liability, claim, damage or expense referred to herein, then the
Indemnifying Party, in lieu of indemnifying such Indemnified Party hereunder,
shall contribute to the amount paid or payable by such Indemnified Party as a
result of such loss, liability, claim, damage or expense in such proportion as
is appropriate to reflect the relative fault of the Indemnifying Party on the
one hand and of the Indemnified Party on the other in connection with the
statements or omissions which resulted in such loss, liability, claim, damage or
expense as well as any other relevant equitable considerations. The relative
fault of the Indemnifying Party and of the Indemnified Party shall be determined
by reference to, among other things, whether the untrue or alleged untrue
statement of a material fact or the omission to state a material fact relates to
information supplied by the Indemnifying Party or by the Indemnified Party and
the parties' relative intent, knowledge, access to information and opportunity
to correct or prevent such statement or omission.

  (h) The Registrable Securities, and any related benefits to the Subscriber
hereunder may be transferred or assigned by the Subscriber to a permitted
transferee or assignee, provided that the Company is given written notice of
such transfer or assignment, stating the name and address of said transferee or
assignee and identifying the Registrable Securities with respect to which such
registration rights are being transferred or assigned; provided further that the
transferee or assignee of such Registrable Securities shall be deemed to have
assumed the obligations of the Subscriber under this Agreement by the acceptance
of such assignment and shall, upon request from the Company, evidence such
assumption by delivery to the Company of a written agreement assuming such
obligations of the Subscriber.

                                      -11-
<PAGE>

  (i) Subscriber covenants and agrees that such Subscriber will comply with the
prospectus delivery requirements of the Securities Act as applicable to such
Subscriber in connection with sales of Registrable Securities pursuant to the
registration statement required hereunder.

     11. No Stock Agreements. There is not in effect on the date hereof any
agreement to which the Company or (to its knowledge) any holders of equity
securities of the Company is a party relating to the voting, transfer or sale of
such securities.

D.   Legend. The certificate representing the Underlying Stock and the Warrants
issued by the Company shall bear the following (or similar) legends:

     THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
     UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR THE
     SECURITIES LAWS OF ANY STATE AND ARE BEING OFFERED AND SOLD IN RELIANCE ON
     EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND
     SUCH LAWS. THESE SECURITIES MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS
     PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR EXEMPTION THEREFROM.

E.   Indemnification. The Subscriber agrees to indemnify and hold harmless the
Company and its officers, managers, members, employees, agents and affiliates
against any and all loss, liability, claim, damage and expense whatsoever
(including without limitation any and all expenses reasonably incurred in
investigating, preparing or defending against any litigation commenced or
threatened or any claim whatsoever) arising out of or based upon any false
representation or warranty or breach or failure by the Subscriber to comply with
any covenant agreement made by the Subscriber herein. The Company agrees to
indemnify and hold harmless the Subscriber and its officers, managers, members,
employees, agents and affiliates against any and all loss, liability, claim,
damage and expense whatsoever (including without limitation any and all expenses
reasonably incurred in investigating, preparing or defending against any
litigation commenced or threatened or any claim whatsoever) arising out of or
based upon any false representation or warranty or breach or failure to comply
with any covenant agreement made by the Company herein.

F.   Modification. Neither this Agreement nor any provision hereof shall be
waived, modified, discharged or terminated except by an instrument in writing
signed by the party against whom any such waiver, modification, discharge or
termination is sought.

G.   Assignability. This Agreement and the rights and obligations hereunder are
not transferable or assignable by the Subscriber.

H.   Applicable Law. This Agreement shall be governed by and construed in
accordance with the laws of the State of Nevada, without regard to principles of
conflicts of law.

                                      -12-
<PAGE>

I.   Survival of Representations and Warranties. All representations and
warranties made by the Subscriber in this Agreement shall survive the execution
and delivery of this Agreement, as well as any investigation at any time made by
or on behalf of the Company and the issue and sale of the Units and Underlying
Stock.

J.   Reliance. The Subscriber understands and acknowledges that the Subscriber's
representations, warranties, acknowledgements and agreements in this Agreement
will be relied upon by the Company in determining the Subscriber's suitability
as a purchaser of Units.

K.   Further Assurances. The Subscriber agrees to provide, if requested, any
additional information that may be requested or required to determine the
Subscriber's eligibility to purchase the Units.

L.   Entire Agreement. This Agreement constitutes the full and entire
understanding and agreement between the parties with regard to the subject
matter hereof and no party shall be liable or bound to any other in any manner
by any representations, warranties, covenants and agreements except as
specifically set forth herein and therein.

M.   Severability. In the event one or more of the provisions of this Agreement
should, for any reason, be held to be invalid, illegal or unenforceable in any
respect, such invalidity, illegality, or unenforceability shall not affect any
other provisions of this Agreement, and this Agreement shall be construed as if
such invalid, illegal or unenforceable provision had never been contained
herein.

                                      -13-
<PAGE>

     IN WITNESS WHEREOF, the undersigned has executed this Agreement as of the
date set forth on this signature page.

     Class and number of Units Subscribed for:   ________________________

     Aggregate Purchase Price:                   ________________________

     _______________________________             ____________________________
     Print Name of Company, Limited              Print Name of Authorized
     Liability Company, Corporation              Representative
     or Trust

     By:____________________________             ____________________________
     Signature of Authorized                     Capacity of Authorized
     Representative                              Representative

     Date: _____________

     Address: _______________________

SUBSCRIPTION ACCEPTED:

AETHLON MEDICAL, INC., a Nevada corporation

By: /s/ James A. Joyce
    ---------------------------------
    Name: James A. Joyce                         Date: ____________, 2007
    Title: CEO

                                      -14-<PAGE>

EXHIBIT 10.42

THIS WARRANT AND THE COMMON SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THIS WARRANT
AND THE COMMON SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD,
OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT UNDER SAID ACT OR AN OPINION OF COUNSEL REASONABLY
SATISFACTORY TO AETHLON MEDICAL, INC. THAT SUCH REGISTRATION IS NOT REQUIRED.

                                  Right to Purchase  __________  of shares of
                                  Common Stock of Aethlon Medical, Inc. (subject
                                  to adjustment as provided herein)

                          COMMON STOCK PURCHASE WARRANT

No. __________                                      Issue Date:_________________

     AETHLON MEDICAL, INC., a corporation organized under the laws of the State
of Nevada (the "Company"), hereby certifies that, for value received, or its
assigns (the "Holder"), is entitled, subject to the terms set forth below, to
purchase from the Company at any time after the Issue Date until 5:00 p.m.,
P.S.T. on the thridanniversary of the Issue Date (the "Expiration Date"), up to
fully paid and nonassessable shares of the common stock of the Company (the
"Common Stock"), at a per share purchase price of $0.50. The aforedescribed
purchase price per share, as adjusted from time to time as herein provided, is
referred to herein as the "Purchase Price." The number and character of such
shares of Common Stock and the Purchase Price are subject to adjustment as
provided herein. The Company may reduce the Purchase Price without the consent
of the Holder.

     As used herein the following terms, unless the context otherwise requires,
have the following respective meanings:

     (a) The term "Company" shall include Aethlon Medical, Inc. and any
corporation which shall succeed or assume the obligations of Aethlon Medical,
Inc. hereunder.

     (b) The term "Common Stock" includes (a) the Company's Common Stock and (b)
any other securities into which or for which any of the securities described in
(a) may be converted or exchanged pursuant to a plan of recapitalization,
reorganization, merger, sale of assets or otherwise.

     (c) The term "Other Securities" refers to any stock (other than Common
Stock) and other securities of the Company or any other person (corporate or
otherwise) which the holder of the Warrant at any time shall be entitled to
receive, or shall have received, on the exercise of the Warrant, in lieu of or
in addition to Common Stock, or which at any time shall be issuable or shall
have been issued in exchange for or in replacement of Common Stock or Other
Securities pursuant to Section 4 or otherwise.

     1.   Exercise of Warrant.

          1.1. Number of Shares Issuable upon Exercise. From and after the Issue
Date through and including the Expiration Date, the Holder hereof shall be
entitled to receive, upon exercise of this Warrant in whole in accordance with
the terms of subsection 1.2 or upon exercise of this Warrant in part in
accordance with subsection 1.3, shares of Common Stock of the Company, subject
to adjustment pursuant to Section 4.

                                       1
<PAGE>

          1.2. Full Exercise. This Warrant may be exercised in full by the
Holder hereof by delivery of an original or facsimile copy of the form of
subscription attached as Exhibit A hereto (the "Subscription Form") duly
executed by such Holder and surrender of the original Warrant within seven (7)
days of exercise, to the Company at its principal office or at the office of its
Warrant Agent (as provided hereinafter), accompanied by payment, in cash, wire
transfer or by certified or official bank check payable to the order of the
Company, in the amount obtained by multiplying the number of shares of Common
Stock for which this Warrant is then exercisable by the Purchase Price then in
effect or by cashless exercise in the manner set forth in Section 2.

          1.3. Partial Exercise. This Warrant may be exercised in part (but not
for a fractional share) by surrender of this Warrant in the manner and at the
place provided in subsection 1.2 except that the amount payable by the Holder on
such partial exercise shall be the amount obtained by multiplying (a) the number
of whole shares of Common Stock designated by the Holder in the Subscription
Form by (b) the Purchase Price then in effect. On any such partial exercise, the
Company, at its expense, will forthwith issue and deliver to or upon the order
of the Holder hereof a new Warrant of like tenor, in the name of the Holder
hereof or as such Holder (upon payment by such Holder of any applicable transfer
taxes) may request, the whole number of shares of Common Stock for which such
Warrant may still be exercised.

          1.4. Company Acknowledgment. The Company will, at the time of the
exercise of the Warrant, upon the request of the Holder hereof acknowledge in
writing its continuing obligation to afford to such Holder any rights to which
such Holder shall continue to be entitled after such exercise in accordance with
the provisions of this Warrant. If the Holder shall fail to make any such
request, such failure shall not affect the continuing obligation of the Company
to afford to such Holder any such rights.

          1.5. Trustee for Warrant Holders. In the event that a bank or trust
company shall have been appointed as trustee for the Holder of the Warrants
pursuant to Subsection 3.2, such bank or trust company shall have all the powers
and duties of a warrant agent (as hereinafter described) and shall accept, in
its own name for the account of the Company or such successor person as may be
entitled thereto, all amounts otherwise payable to the Company or such
successor, as the case may be, on exercise of this Warrant pursuant to this
Section 1.

          1.6 Delivery of Stock Certificates, etc. on Exercise. The Company
agrees that the shares of Common Stock purchased upon exercise of this Warrant
shall be deemed to be issued to the Holder hereof as the record owner of such
shares as of the close of business on the date on which this Warrant shall have
been surrendered and payment made for such shares as aforesaid. As soon as
practicable after the exercise of this Warrant in full or in part, and in any
event within five (5) days thereafter, the Company at its expense (including the
payment by it of any applicable issue taxes) will cause to be issued in the name
of and delivered to the Holder hereof, or as such Holder (upon payment by such
Holder of any applicable transfer taxes) may direct in compliance with
applicable securities laws, a certificate or certificates for the number of duly
and validly issued, fully paid and nonassessable shares of Common Stock (or
Other Securities) to which such Holder shall be entitled on such exercise, plus,
in lieu of any fractional share to which such Holder would otherwise be
entitled, cash equal to such fraction.

     2.   Registration Rights. The Company shall file a registration statement
on Form SB-2 or other appropriate registration form under the Securities Act
(the "Registration Statement") for the registration of the shares of Common
Stock underlying this Warrant (the "Warrant Shares") and shall use its
reasonable best efforts to maintain the Registration Statement effective so long
as this Warrant is outstanding (the "Effectiveness Period"). The Company shall
file such Registration Statement no later than sixty (60) days after August 13,
2007; provided, however, the Company will not be obligated to register more than
33% of its issued and outstanding shares of Common Stock on such registration
statement. If the number of shares of Common Stock and the Warrant Shares
proposed to be registered thereunder exceeds such 33% limitation, the Company

                                       2
<PAGE>

will cut back the number of shares being registered in order for it to adhere to
such 33% limitation, and such cut back will be applied to the holders of the
shares being registered (including the Holder hereof) on a pro rata basis. The
Company shall also use its best efforts to ensure that such Registration
Statement is declared effective within one hundred and eighty (180) calendar
days from August 13, 2007. Except as otherwise expressly set forth, the Company
shall bear all expenses incurred by the Company in compliance with this
registration obligation of the Company, including, without limitation, all
registration and filing fees, printing expenses, fees and disbursements of
counsel for the Company incurred in connection with any registration,
qualification or compliance concerning the Warrant Shares.

     3.   Adjustment for Reorganization, Consolidation, Merger, etc.

          3.1. Reorganization, Consolidation, Merger, etc. In case at any time
or from time to time, the Company shall (a) effect a reorganization, (b)
consolidate with or merge into any other person or (c) transfer all or
substantially all of its properties or assets to any other person under any plan
or arrangement contemplating the dissolution of the Company, then, in each such
case, as a condition to the consummation of such a transaction, proper and
adequate provision shall be made by the Company whereby the Holder of this
Warrant, on the exercise hereof as provided in Section 1, at any time after the
consummation of such reorganization, consolidation or merger or the effective
date of such dissolution, as the case may be, shall receive, in lieu of the
Common Stock (or Other Securities) issuable on such exercise prior to such
consummation or such effective date, the stock and other securities and property
(including cash) to which such Holder would have been entitled upon such
consummation or in connection with such dissolution, as the case may be, if such
Holder had so exercised this Warrant, immediately prior thereto, all subject to
further adjustment thereafter as provided in Section 4.

          3.2. Dissolution. In the event of any dissolution of the Company
following the transfer of all or substantially all of its properties or assets,
the Company, prior to such dissolution, shall at its expense deliver or cause to
be delivered the stock and other securities and property (including cash, where
applicable) receivable by the Holder of the Warrants after the effective date of
such dissolution pursuant to this Section 3 to a bank or trust company (a
"Trustee") having its principal office in Los Angeles, California, as trustee
for the Holder of the Warrants.

          3.3. Continuation of Terms. Upon any reorganization, consolidation,
merger or transfer (and any dissolution following any transfer) referred to in
this Section 3, this Warrant shall continue in full force and effect and the
terms hereof shall be applicable to the Other Securities and property receivable
on the exercise of this Warrant after the consummation of such reorganization,
consolidation or merger or the effective date of dissolution following any such
transfer, as the case may be, and shall be binding upon the issuer of any Other
Securities, including, in the case of any such transfer, the person acquiring
all or substantially all of the properties or assets of the Company, whether or
not such person shall have expressly assumed the terms of this Warrant as
provided in Section 4. In the event this Warrant does not continue in full force
and effect after the consummation of the transaction described in this Section
3, then only in such event will the Company's securities and property (including
cash, where applicable) receivable by the Holder of the Warrants be delivered to
the Trustee as contemplated by Section 3.2.

     4.   Extraordinary Events Regarding Common Stock. In the event that the
Company shall (a) issue additional shares of the Common Stock as a dividend or
other distribution on outstanding Common Stock, (b) subdivide its outstanding
shares of Common Stock, or (c) combine its outstanding shares of the Common
Stock into a smaller number of shares of the Common Stock, then, in each such
event, the Purchase Price shall, simultaneously with the happening of such
event, be adjusted by multiplying the then Purchase Price by a fraction, the
numerator of which shall be the number of shares of Common Stock outstanding
immediately prior to such event and the denominator of which shall be the number
of shares of Common Stock outstanding immediately after such event, and the
product so obtained shall thereafter be the Purchase Price then in effect. The

                                       3
<PAGE>

Purchase Price, as so adjusted, shall be readjusted in the same manner upon the
happening of any successive event or events described herein in this Section 4.
The number of shares of Common Stock that the Holder of this Warrant shall
thereafter, on the exercise hereof as provided in Section 1, be entitled to
receive shall be adjusted to a number determined by multiplying the number of
shares of Common Stock that would otherwise (but for the provisions of this
Section 4) be issuable on such exercise by a fraction of which (a) the numerator
is the Purchase Price that would otherwise (but for the provisions of this
Section 4) be in effect, and (b) the denominator is the Purchase Price in effect
on the date of such exercise.

     5.   Certificate as to Adjustments. In each case of any adjustment or
readjustment in the shares of Common Stock (or Other Securities) issuable on the
exercise of the Warrants, the Company at its expense will promptly cause its
Chief Financial Officer or other appropriate designee to compute such adjustment
or readjustment in accordance with the terms of the Warrant and prepare a
certificate setting forth such adjustment or readjustment and showing in detail
the facts upon which such adjustment or readjustment is based, including a
statement of (a) the consideration received or receivable by the Company for any
additional shares of Common Stock (or Other Securities) issued or sold or deemed
to have been issued or sold, (b) the number of shares of Common Stock (or Other
Securities) outstanding or deemed to be outstanding, and (c) the Purchase Price
and the number of shares of Common Stock to be received upon exercise of this
Warrant, in effect immediately prior to such adjustment or readjustment and as
adjusted or readjusted as provided in this Warrant. The Company will forthwith
mail a copy of each such certificate to the Holder of the Warrant and any
Warrant Agent of the Company (appointed pursuant to Section 11 hereof).

     6.   Reservation of Stock, etc. Issuable on Exercise of Warrant; Financial
Statements. The Company will at all times reserve and keep available, solely for
issuance and delivery on the exercise of the Warrants, all shares of Common
Stock (or Other Securities) from time to time issuable on the exercise of the
Warrant. This Warrant entitles the Holder hereof to receive copies of all
financial and other information distributed or required to be distributed to the
holders of the Company's Common Stock.

     7.   Assignment; Exchange of Warrant. Subject to compliance with applicable
securities laws, this Warrant, and the rights evidenced hereby, may be
transferred by any registered holder hereof (a "Transferor"). On the surrender
for exchange of this Warrant, with the Transferor's endorsement in the form of
Exhibit B attached hereto (the "Transferor Endorsement Form") and together with
an opinion of counsel reasonably satisfactory to the Company that the transfer
of this Warrant will be in compliance with applicable securities laws, the
Company at its expense, but with payment by the Transferor of any applicable
transfer taxes, will issue and deliver to or on the order of the Transferor
thereof a new Warrant or Warrants of like tenor, in the name of the Transferor
and/or the transferee(s) specified in such Transferor Endorsement Form (each a
"Transferee"), calling in the aggregate on the face or faces thereof for the
number of shares of Common Stock called for on the face or faces of the Warrant
so surrendered by the Transferor. No such transfers shall result in a public
distribution of the Warrant.

     8.   Replacement of Warrant. On receipt of evidence reasonably satisfactory
to the Company of the loss, theft, destruction or mutilation of this Warrant
and, in the case of any such loss, theft or destruction of this Warrant, on
delivery of an indemnity agreement or security reasonably satisfactory in form
and amount to the Company or, in the case of any such mutilation, on surrender
and cancellation of this Warrant, the Company at its expense, twice only, will
execute and deliver, in lieu thereof, a new Warrant of like tenor.

     9.   Warrant Agent. The Company may, by written notice to the Holder of the
Warrant, appoint an agent (a "Warrant Agent") for the purpose of issuing Common
Stock (or Other Securities) on the exercise of this Warrant pursuant to Section
1, exchanging this Warrant pursuant to Section 7, and replacing this Warrant
pursuant to Section 8, or any of the foregoing, and thereafter any such
issuance, exchange or replacement, as the case may be, shall be made at such
office by such Warrant Agent.

                                       4
<PAGE>

     10.   Transfer on the Company's Books. Until this Warrant is transferred on
the books of the Company, the Company may treat the registered holder hereof as
the absolute owner hereof for all purposes, notwithstanding any notice to the
contrary.

     11.   Notices. All notices, demands, requests, consents, approvals, and
other communications required or permitted hereunder shall be in writing and,
unless otherwise specified herein, shall be (i) personally served, (ii)
deposited in the mail, registered or certified, return receipt requested,
postage prepaid, (iii) delivered by reputable air courier service with charges
prepaid, or (iv) transmitted by hand delivery, telegram, or facsimile, addressed
as set forth below or to such other address as such party shall have specified
most recently by written notice. Any notice or other communication required or
permitted to be given hereunder shall be deemed effective (a) upon hand delivery
or delivery by facsimile, with accurate confirmation generated by the
transmitting facsimile machine, at the address or number designated below (if
delivered on a business day during normal business hours where such notice is to
be received), or the first business day following such delivery (if delivered
other than on a business day during normal business hours where such notice is
to be received) or (b) on the second business day following the date of mailing
by express courier service, fully prepaid, addressed to such address, or upon
actual receipt of such mailing, whichever shall first occur. The addresses for
such communications shall be: (i) if to the Company to: Aethlon Medical, Inc.,
3030 Bunker Hill Street, Suite 4000, San Diego, California 92109, FAX (858)
332-1739, with a copy by facsimile only to: Richardson & Patel LLP, 10900
Wilshire Boulevard, Suite 500, Los Angeles, CA 90024, Attn: Nimish Patel, Esq.,
telecopier: (310) 208-1154, (ii) if to the Holder, to the address and facsimile
number listed on the first paragraph of this Warrant.

     12.   Miscellaneous. This Warrant and any term hereof may be changed,
waived, discharged or terminated only by an instrument in writing signed by the
party against which enforcement of such change, waiver, discharge or termination
is sought. This Warrant shall be construed and enforced in accordance with and
governed by the laws of California. Any dispute relating to this Warrant shall
be adjudicated in City of Los Angeles in the State of California. The headings
in this Warrant are for purposes of reference only, and shall not limit or
otherwise affect any of the terms hereof. The invalidity or unenforceability of
any provision hereof shall in no way affect the validity or enforceability of
any other provision.

     IN WITNESS WHEREOF, the Company has executed this Warrant as of the date
first written above.

                              AETHLON MEDICAL, INC.

                              By: /s/ James A. Joyce
                                  ----------------------------------------------
                                  Name: James A. Joyce
                                  Title: Chairman and Chief Executive Officer

Witness:

_______________________

                                       5
<PAGE>

                                    EXHIBIT A

                              FORM OF SUBSCRIPTION
                   (to be signed only on exercise of Warrant)

TO:  AETHLON MEDICAL, INC.

The undersigned, pursuant to the provisions set forth in the attached Warrant
(No.____), hereby irrevocably elects to purchase (check applicable box):

___    ________ shares of the Common Stock covered by such Warrant.

The undersigned herewith makes payment of the full purchase price for such
shares at the price per share provided for in such Warrant, which is
$___________. Such payment takes the form of (check applicable box or boxes):

___    $__________ in lawful money of the United States

The undersigned requests that the certificates for such shares be issued in the
name of, and delivered to _____________________________________________________
whose address is _______________________________________________________________
_______________________________________________________________________________.

The undersigned represents and warrants that all offers and sales by the
undersigned of the securities issuable upon exercise of the within Warrant shall
be made pursuant to registration of the Common Stock under the Securities Act of
1933, as amended (the "Securities Act"), or pursuant to an exemption from
registration under the Securities Act.

Dated:___________________

Signature:_____________________________
(Signature must conform to name of holder as
specified on the face of the Warrant)

Address: __________________________
         __________________________
         __________________________

                                        6
<PAGE>

                                    EXHIBIT B

                         FORM OF TRANSFEROR ENDORSEMENT
                   (To be signed only on transfer of Warrant)

     For value received, the undersigned hereby sells, assigns, and transfers
unto the person(s) named below under the heading "Transferees" the right
represented by the within Warrant to purchase the percentage and number of
shares of Common Stock of AETHLON MEDICAL, INC. to which the within Warrant
relates specified under the headings "Percentage Transferred" and "Number
Transferred," respectively, opposite the name(s) of such person(s) and appoints
each such person Attorney to transfer its respective right on the books of
AETHLON MEDICAL, INC. with full power of substitution in the premises.

--------------------------------------------------------------------------------
Transferees             Percentage Transferred           Number Transferred
--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

Dated:  ______________, ___________       _____________________________________
                                          (Signature must conform to name of
                                          holder as specified on the face of
                                          the warrant)

Signed in the presence of:

__________________________________        _____________________________________
         (Name)                           _____________________________________
                                                        (address)

ACCEPTED AND AGREED:                      _____________________________________
[TRANSFEREE]                              _____________________________________
                                                        (address)
__________________________________
         (Name)

                                        7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00136-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00136-of-00352.parquet"}]]